Sight Sciences (SGHT) Stock Price, News & Analysis

Company Overview

Sight Sciences, Inc. is an ophthalmic medical device company focused on developing innovative technologies to diagnose and treat eye conditions. Since its founding in 2011, the company has concentrated on ophthalmic solutions for ocular surface disease and glaucoma, combining engineering expertise with clinical research to address unmet needs in eye care.

The company’s flagship product, the TearCare® System, is designed to treat Meibomian Gland Dysfunction (MGD), a leading cause of evaporative dry eye disease. The system delivers controlled thermal energy to the eyelids and simultaneously applies natural gland expression, helping to restore gland function and improve tear film quality. In parallel, Sight Sciences is advancing a pipeline of diagnostic and therapeutic devices aimed at better managing glaucoma and other anterior segment disorders.

Headquartered in Menlo Park, California, Sight Sciences has established a U.S. commercial footprint and is pursuing international distribution through strategic partnerships. The company supports eye care professionals with training programs, clinical support, and ongoing education to facilitate the adoption of its technologies and to ensure optimal patient outcomes.

Under the leadership of Chief Executive Officer Keith Walter and a management team with extensive experience in ophthalmology and medical technology, Sight Sciences remains committed to driving clinical evidence and expanding its product portfolio. The company continues to invest in research and development, leveraging data from multicenter trials to advance its mission of improving the quality of life for patients with eye disease.

Key Stats

• Today's Range: $3.41 to $4.27
• 50-Day Range: $2.81 to $4.34
• 52-Week Range: $2.03 to $8.45
• Volume: 267,059 shs
• Average Volume: 213,085 shs
• Market Capitalization: $179.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.10
• Consensus Rating: Hold

Sight Sciences Stock Analysis - MarketRank™

Sight Sciences scored higher than 24% of companies evaluated by MarketBeat, and ranked 865th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Sight Sciences has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 2 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Sight Sciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sight Sciences are expected to grow in the coming year, from ($0.99) to ($0.91) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sight Sciences is -3.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sight Sciences is -3.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sight Sciences has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.26% of the float of Sight Sciences has been sold short.

Short Interest Ratio / Days to Cover

Sight Sciences has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Sight Sciences has recently decreased by 4.96%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sight Sciences does not currently pay a dividend.

Dividend Growth

Sight Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.26% of the float of Sight Sciences has been sold short.

Short Interest Ratio / Days to Cover

Sight Sciences has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Sight Sciences has recently decreased by 4.96%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Sight Sciences this week, compared to 3 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sight Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.90% of the stock of Sight Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

55.51% of the stock of Sight Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SGHT Stock Analysis - Frequently Asked Questions

How have SGHT shares performed this year?

Sight Sciences' stock was trading at $3.64 at the beginning of 2025. Since then, SGHT stock has decreased by 4.7% and is now trading at $3.47.

How were Sight Sciences' earnings last quarter?

Sight Sciences, Inc. (NASDAQ:SGHT) announced its earnings results on Thursday, May, 8th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.01. The firm earned $17.51 million during the quarter, compared to the consensus estimate of $16.51 million. Sight Sciences had a negative trailing twelve-month return on equity of 54.62% and a negative net margin of 63.24%.
Read the conference call transcript.

When did Sight Sciences IPO?

Sight Sciences (SGHT) raised $150 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 6,980,000 shares at $20.00-$23.00 per share.

How do I buy shares of Sight Sciences?

Shares of SGHT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sight Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sight Sciences investors own include American Water Works (AWK), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Waste Connections (WCN), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:SGHT
• CIK: 1531177
• Web: www.sightsciences.com
• Phone: 877-266-1144
• Fax: N/A
• Employees: 210
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.10
• High Stock Price Target: $5.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +18.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.51 million
• Net Margins: -63.24%
• Pretax Margin: -62.91%
• Return on Equity: -54.62%
• Return on Assets: -34.92%

Debt

• Debt-to-Equity Ratio: 0.51
• Current Ratio: 10.47
• Quick Ratio: 9.99

Sales & Book Value

• Annual Sales: $79.87 million
• Price / Sales: 2.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.72 per share
• Price / Book: 2.01

Miscellaneous

• Outstanding Shares: 51,700,000
• Free Float: 36,756,000
• Market Cap: $178.37 million
• Optionable: Optionable
• Beta: 2.47